In modern health care, manufactured materials are commonly used to restore, repair or maintain structure or function in the body. These substances, known as bio-materials, are found in virtually every application ranging from dental restoratives to surgical implants and prosthetics.
Like fingerprints, biochemistries are individual and the effects of exposure to modern bio-materials (and their reactive by-products) vary from person to person. Exposure that proves benign to one individual may prove to be extremely harmful or toxic to another.
Negative effects have been know to range from mild irritation to extreme reactions such as long term illness, dysfunction or damage. As new and complex materials and alloys are continually developed, the impact that these materials present upon an individual’s body chemistry must be considered.
Only clinical testing and analysis of a patient’s unique immunological record can reveal the chemical compounds against which antibodies have been formed. This, in turn, allows offending materials to be identified and reaction forecasts to be made. With this information, health care providers can make informed decisions about the bio-material they choose to meet the need of each patient. This can be especially important in cases when a patient exhibits atypical health complications or sensitivities. Being tested for materials reactivity prior to any procedure involving the use of bio-materials is also one way patients can rest assured that the materials being used in their bodies are safe for them.
Clifford Materials Reactivity Testing (CMRT) is a comprehensive clinical blood test that screens for individual systemic sensitivity to bio-materials through antibody detection. The process begins with the blood serum sample sent by a licensed health care professional in the prepaid, overnight shipping kit we provide. Clifford Consulting & Research normally processes this sample on the day it is received to analyze the patient’s unique antibody record. This is done by screening the blood sample against 89 chemical groups and families and measuring the reaction to each. These individual reactions are then cross-referenced against the largest professionally maintained database of trade name bio-medical composites, alloys and other materials of its kind in the world.
The result is a multi-sectional report that designates the donor patient’s personal results of these potential positive or negative reactions to every material in the database alphabetically by trade name. This report assists the doctor in choosing or eliminating materials that are clinically screened for greatest measure of safety for use in the patient’s body, even in time-sensitive situations.
Despite the unprecedented depth of screening information that CMRT offers health care providers about their patient’s sensitivities, it is not a diagnosis or prognosis of any condition. Any interpretation or inference of the data CMRT
provides remains strictly the doctor’s responsibility to determine.
1. Provide objective laboratory evaluation which is specific to the
2. Offers a measure of guidance for the doctor in choosing the
treatment plan and materials before expensive and involved
placements have been done.
3. Helps facilitate informed choice and consent with all parties
4. Helps to minimize the risk of adverse outcomes and the necessity for
expensive, exotic procedures and counter-measures after structure
and foundation are lost.
5. Is a valuable due-diligence process that contributes to the total
6. Substantially enhances ‘peace of mind’ for both patients and
CMRT does not evaluate materials for galvanic charges, inter product chemical reactions or their interactions which is not determined by antigen/antibody reactions.